Clinical Trial - Trial ChiCTR2200055533
Access comprehensive clinical trial information for ChiCTR2200055533 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Xuhui Central Hospital and is currently Recruiting. The study focuses on gastric cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Group A (immunotherapy group): PD-1 mAb: Sintilimab 200mg, repeated every three weeks; Or Camrelizumab 200 mg, repeated every two weeks; Or Nivolumab 3mg/kg, repeated every two weeks; Or Pembrolizumab 200mg, repeated every three weeks (biweekly or three-week repetition is determined according to the cycle of chemotherapy regimen; domestic or imported drugs are selected according to the economic conditions of patients); Different kinds of PD-1 monoclonal antibodies were selected for the third-line treatment of patients who had failed to PD-1/PD-L1 monoclonal antibodies or CTLA-4 monoclonal antibodies in the past. Group B (apatinib group): Apatinib 500mg QD orally, repeated every 14 or 21 days (determined according to the cycle of chemotherapy regimen). Chemotherapy drugs: Patients with good general status and good tolerance choose the combined scheme: Cisplatin/Oxaliplatin+Tegafur/Capecitabine, Paclitaxel/Docetaxel/Albumin paclitaxel+Tegafur/Capecitabine, mFOLFOX6/mFOLFIRI, etc. are feasible, and patients with poor tolerance choose single drug treatment. In principle, the drugs selected in the research should not fail in the first-line and second-line treatment.
Sponsor & Location
Shanghai Xuhui Central Hospital
Self-funded
Timeline & Enrollment
Phase 2
N/A
Dec 31, 2025
ICD-10 Classifications
Data Source
Chinese Clinical Trial Registry
ChiCTR2200055533
Non-Device Trial